Abstract |
Src tyrosine kinase is a therapeutic target for bone diseases that has been validated by gene knockout studies. Furthermore, in vitro cellular studies implicate that Src has a positive regulatory role in osteoclasts and a negative regulatory role in osteoblasts. The potential use of Src inhibitors for osteoporosis therapy has been previously shown by novel bone-targeted ligands of the Src SH2 (e.g., AP22408) and non-bone-targeted, ATP-based inhibitors of Src kinase. Significant to this study, compounds 2-12 exemplify novel analogues of known pyrrolopyrimidine and pyrazolopyrimidine template-based Src kinase inhibitors that incorporate bone-targeting group modifications designed to provide tissue (bone) selectivity and diminished side effects. Accordingly, we report here the structure-based design, synthetic chemistry and biological testing of these compounds and proof-of-concept studies thereof.
|
Authors | Raji Sundaramoorthi, William C Shakespeare, Terence P Keenan, Chester A Metcalf 3rd, Yihan Wang, Ukti Mani, Merry Taylor, Shuangying Liu, Regine S Bohacek, Surinder S Narula, David C Dalgarno, Marie Rose van Schravandijk, Sheila M Violette, Shuenn Liou, Susan Adams, Mary K Ram, Jeffrey A Keats, Manfred Weigle, Tomi K Sawyer, Manfred Weigele |
Journal | Bioorganic & medicinal chemistry letters
(Bioorg Med Chem Lett)
Vol. 13
Issue 18
Pg. 3063-6
(Sep 15 2003)
ISSN: 0960-894X [Print] England |
PMID | 12941334
(Publication Type: Journal Article)
|
Chemical References |
- Enzyme Inhibitors
- Purines
- Pyrimidines
- Adenosine Triphosphate
- src-Family Kinases
|
Topics |
- Adenosine Triphosphate
(analogs & derivatives)
- Animals
- Bone Diseases
(drug therapy)
- Drug Design
- Enzyme Inhibitors
(chemical synthesis, pharmacology)
- Humans
- Inhibitory Concentration 50
- Models, Molecular
- Osteoporosis
(drug therapy)
- Purines
(chemical synthesis, pharmacology)
- Pyrimidines
(chemical synthesis, pharmacology)
- Structure-Activity Relationship
- src-Family Kinases
(antagonists & inhibitors)
|